sickle cell disease

Patients

‘Build back better’ cannot mean longer waiting times for cha...

Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients in the UK.

News

Joy as sickle cell patients get access to Novartis' Adakveo ...

People living with sickle cell disease (SCD) in England and Wales will be able to get access to treatment with Novartis' Adakveo, thanks to a special arrangement between the drugmaker and N

News

Vertex builds in gene editing yet again, with $1.2bn Arbor d...

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that coul

News

MHRA grants bluebird 'innovation passport' for sickle cell t...

bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disord...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage tr

Events